May. 20 at 10:11 AM
$ANIP ANIP is now selling INZIRQO (hydrochlorothiazide) for Oral Suspension and TEZRULY (terazosin) Oral Solution, but have yet to announce their launch. Both have no competition and are patent protected until 2041 or later. They both address unmet needs for patients who have trouble swallowing pill and capsule versions formulations of theses drugs (e.g. hospital, assisted living)
INZIRQO is indicated for Hypertension and Edema. In 2022, over 38 million prescriptions hydrochlorothiazide were filled in the US. If INZIRQO captures 3 % of the market it could generate approximately
$475 million.
TEZRULY is an alpha-1 blocker indicated for Benign Prostatic Hyperplasia and Hypertension. In 2022, over 28 million prescriptions for the top alpha-1 blockers were filled in the US. IF TEZRULY capture 3% of this market it could add another
$400 million in revenue.
Non of these drugs appear factored into current PPS.
